Patient sues GLP-1 drugmaker over alleged permanent vision loss
Juste les faits

Patient sues GLP-1 drugmaker over alleged permanent vision loss

Résumé

A lawsuit claims the diabetes drug Ozempic caused non-arteritic anterior ischemic optic neuropathy, leaving the plaintiff legally blind, and alleges the manufacturer failed to warn about the risk.

A Texas man who took the GLP-1 medication Ozempic for diabetes says he lost vision in both eyes and is now legally blind, filing a lawsuit that accuses the drugmaker of failing to warn about a rare eye condition. The complaint alleges that the drug caused non-arteritic anterior ischemic optic neuropathy (NAION), a disorder that can lead to rapid vision loss and blindness and affects roughly two to ten people per 100,000 annually in the United States, according to the American Academy of Ophthalmology.

The plaintiff’s attorney, Grace Chandler, told a live interview that the patient “will never see his wife smile” and will be unable to watch his grandchildren grow up, emphasizing the impact on his daily life. Chandler said studies identify GLP-1 drugs as an independent risk factor for NAION and argued that manufacturers are required to include such risks on product labels.

Chandler noted that warning language for NAION appears on drug labels in Canada, Europe and Australia, but not on U.S. labels for Ozempic, Wegovy or Zepbound. The Food and Drug Administration is reviewing a possible link between semaglutide, the active ingredient in these drugs, and NAION, though no formal determination has been made.

The lawsuit adds to a growing number of legal actions against GLP-1 drugmakers alleging serious side effects from weight-loss and diabetes treatments.

Continuez à lire — gratuitement

Créez un compte gratuit pour suivre l'actualité. Aucune carte requise.